Autologous TILs use their native TCRs to recognize the tumor neoantigen peptide on HLA class II and directly kill the presenting cell via perforin/granzyme release and Fas–FasL–mediated apoptosis, aided by cytotoxic cytokines (e.g., IFN-γ, TNF).